Dr. Paul Thielking

Numinus Wellness Inc. (OTCQX: NUMIF) announced the launch of its new clinical program, ketamine for chronic and serious medical illness, to be first introduced at Utah, BC and Quebec clinics and then expanded to Numinus' remaining facilities. The company’s model includes...

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and evidence-based psychedelic-assisted therapies, announced that its research division, Numinus Bioscience, has developed a psilocybin-containing tea bag for use in clinical research and...

Novamind Inc. (OTCQB: NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site. "The Psilocybin Trial is a...

Novamind (Canadian: NM) (OTCQB: NVMDF), a company in the psychedelics space that operates several mental health clinics in Utah, announced a new program for palliative care patients experiencing chronic and serious illnesses. The program will take place at Novamind’s recently-opened...